Background: Despite good prognosis in most cases of lymph node (LN)-negative breast cancer, individual patients may have markedly different clinical outcomes. Here, we investigated the prognostic significance of HER2/neu overexpression in these tumors.
introduction
Since 2001, breast cancer has become the most common malignancy among Korean women, with a rapidly escalating incidence rate [1] . In recent years, the number of axillary lymph node (LN)-negative breast cancer cases has increased because of screening mammography [1, 2] . Whereas the majority of LN-negative breast cancers are associated with good prognosis, markedly different clinical outcomes are possible. Indeed, 30% of patients with LN-negative breast cancer present with distant metastasis and die as a result of systemic disease [3] . However, the optimal definition of relapse risk profiles for these patients is currently controversial. In recent years, extensive attempts have been made to identify potential prognostic markers and to clearly define groups of LN-negative breast cancer patients with poor prognosis [4] [5] [6] [7] . Among them, the significance of HER2/neu has been a focus of intense interest.
HER2/neu is a glycoprotein that belongs to the epidermal growth factor receptor (EGFR) family, a group of transmembrane receptors with intracellular tyrosine kinase activity. The protein is overexpressed in 20%-30% of all breast cancers [8] . Population-based and retrospective analyses show that high expression of HER2/neu is an adverse prognostic factor associated with poorly differentiated high-grade tumors, high rates of cell proliferation and LN involvement, and relative resistance to certain types of chemotherapy [4, [9] [10] [11] . However, the prognostic value of HER2/neu levels, particularly in patients with LN-negative breast cancer, remains ambiguous [7, 12, 13] .
Since the ninth St Gallen consensus, HER2/neu status has been established as sufficiently reliable to define relapse risk, leading to the division of breast cancer patients into low-, intermediate-, and high-risk categories [14] . Based [15] .
In the present study, we assay HER2/neu expression using a tissue microarray method in patients with LN-negative breast cancer and evaluate the association of HER2/neu overexpression and other clinicopathological characteristics with clinical outcomes. The prognostic value of HER2/neu overexpression in LN-negative breast cancer is further analyzed in combination with the recently modified St Gallen classification.
materials and methods

patients and tissues
Tissue samples were obtained from specimens of 359 patients with LNnegative primary invasive breast cancer subjected to curative surgical resection from January 1993 to December 1998 at the Asan Medical Center. All tissues were fixed in 10% buffered formalin and embedded in paraffin. Clinical informations, including patient age at initial diagnosis, sex, type of surgery, adjuvant therapy, tumor recurrence or distant metastasis, and follow-up status, were retrospectively obtained from hospital medical records. Pathologic parameters, including tumor size, histologic subtype, histologic grade, and nuclear grade, were evaluated from the archived hematoxylin and eosin (H&E)-stained slides. The histologic grade was assessed using a modified Bloom-Richardson classification and the nuclear grade evaluated according to a modification of Black's nuclear grading system.
tissue microarray methods
Tissue microarrays were constructed as described previously [16] . Briefly, 359 formalin-fixed, paraffin-embedded, tissue blocks containing breast carcinoma specimens were retrieved from the archives of the Institute of Pathology. Representative areas of each invasive carcinoma were identified on the corresponding H&E-stained slides. Tissue cylinders with a diameter of 1 mm were punched from each donor tissue block and entered into a recipient paraffin block using a Tissue Microarrayer (Beecher Instruments, Silver Spring, MD). The recipient paraffin block was subsequently cut and slices transferred with adhesive tape to coated slides. Next, slides were dipped in paraffin to prevent oxidation. Each sample was arrayed in triplicate to minimize tissue loss and to overcome tumor heterogeneity.
immunohistochemical staining
Tissue microarray sections were immunohistochemically stained for HER2/ neu, estrogen receptor (ER), progesterone receptor (PR), EGFR, and p53. Briefly, tissue microarray slides generated from paraffin-embedded tissue blocks were deparaffinized and rehydrated for 5 min. After microwave pretreatment in citrate buffer (pH 6.0) for antigen retrieval, slides were immersed in 0.3% (vol/vol) hydrogen peroxide for 20 min to block endogenous peroxidase activity. Slides were washed and incubated overnight at 4°C with primary antibodies against ER (1 : 50 dilution; Dinona, Seoul, Korea), PR (1 : 100 dilution; Dinona), p53 (1 : 1600 dilution; DAKO Corporation, Carpinteria, CA), and HER2/neu (1 : 250 dilution; DAKO). After a second incubation with a biotinylated anti-goat antibody, slides were incubated with peroxidase-labeled streptavidin. Reaction products were visualized by immersing the slides in diaminobenzidine tetrachloride and counterstaining with Harris hematoxylin. Immunostaining for EGFR was carried out using the EGFRpharmDx assay detection system (prediluted, DAKO).
evaluation of immunohistochemical samples
All immunohistochemically stained samples were scored independently in a blind manner by two pathologists who had no patient information. Immunostaining for EGFR was interpreted as positive when at least 10% of tumor cells showed strong membranous staining. Cases were considered positive for ER or PR when strong nuclear staining was observed in at least 10% of tumor cells examined [9] . p53 immunostaining was defined as positive when >10% of the tumor cells exhibited strong nuclear staining. Immunostaining for HER2/neu was interpreted as positive in cases of strong (3+) membranous staining in at least 10% of tumor cells, whereas scores of 0 to 2+ were regarded as negative.
statistical analysis
The relationships between HER2/neu expression and other clinicopathological parameters, such as tumor size, ER, PR, histologic grade, EGFR, and p53, were compared using the v 2 or Fisher's exact probability tests, where appropriate. The Kaplan-Meier method was used to estimate survival, and differences were analyzed with the log-rank test. Disease-free survival (DFS) was defined as the time from the day of operation to a documented recurrence or death from any other cause. Overall survival (OS) was measured from the date of the operation to the last follow-up or death. Cox proportional hazards model was employed for multivariate analysis of prognostic factors. All statistical analyses were carried out using SPSS software (version 14.0), and P <0.05 was defined as statistically significant.
results
clinicopathological characteristics
The median age of the 359 patients was 47 years (range 25-88 years), and all but four patients were women. The major histologic type was invasive ductal carcinoma (331 cases), followed by invasive lobular (eight cases), mucinous (seven cases), metaplastic (six cases), medullary (five cases), papillary (one case), and tubular (one case) carcinoma. Modified radical mastectomy was carried out on 328 patients and breastconserving surgery on 31 patients. After surgery, 45% (159 of 359) of the patients received some form of adjuvant chemotherapy. Specifically, 150 patients received six cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), eight were given six cycles of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF), and one received four cycles of adriamycin, followed by six cycles of CMF. Antihormonal therapy was administered to 185 patients. Table 2 ). The 10-year DFS rate was 81.2% in the HER2/ neu-negative group and 61.8% in the HER2/neu-positive group (P value 0.000), whereas the 10-year OS rates in the two groups were 85.7% and 63.9%, respectively (P value 0.000) (Figure 1 ). On multivariate analysis using Cox proportional hazards model after adjusting for age, histologic grade, hormonal receptor status, and tumor size, three factors (tumor size, PR status, and HER2/neu) were of independent prognostic relevance to the 10-year DFS rate (Table 3) . However, only HER2/neu overexpression [odds ratio (OR) = 3.086; 95% confidence interval (CI) 1.696-5.612] and tumor size (OR = 3.038; 95% CI 1.573-5.870) were identified as independent prognostic factors for the 10-year OS rate (Table 4) .
survival analysis according to HER2/neu overexpression in the St Gallen risk group
Ten-year DFS rates according to the HER2/neu status for several groups of patients are summarized in Table 5 . HER2/ neu overexpression was a statistically significant predictive marker of poor prognosis, even in subgroups with known poor prognostic factors, such as large tumor size (>2 cm), ER-or 
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PR-negative tumors, or tumors of high histologic grades (2 or 3). Figure 2 presents the survival curve stratified by the combination of HER2/neu overexpression and hormone receptor status. The patient group with positive HER2/neu and negative hormone receptor status displayed significantly worse DFS (P value 0.000) and OS (P value 0.000) values than did other subgroups. Based on these findings, we analyzed the DFS and OS rates of LN-negative breast cancer patients with or without HER2/neu overexpression in subgroups defined by the recently modified St Gallen classification. Subjects with LN-negative breast cancer were categorized into low risk (28 patients), intermediate risk without HER2/neu overexpression (248 patients), and intermediate risk with HER2/neu overexpression (83 patients) categories. The 10-year DFS rates for the three groups were 96.3%, 79.6%, and 61.8% (P-value 0.000), and 10-year OS rates were 96.3%, 84.7%, and 63.9% (P value 0.000), respectively ( Figure 3 ).
discussion
It is currently not possible to identify specific patients among the LN-negative breast cancer population who will eventually succumb to the disease. Traditionally, the prognostic factors for patients with LN-negative breast cancer include age, tumor size, histological grade, and hormonal status [6, 9, [17] [18] [19] . Molecular markers for poor prognosis have been increasingly investigated as potential prognostic factors. To date, no universally accepted markers for this group of patients have been isolated [5, 20] . Recently, HER2/neu expression has attracted significant interest as a potential prognostic and [20, 21] . In general, HER2/neu overexpression is correlated with tumor size or number of involved LNs and is more often observed in advanced breast cancer [21] . Several studies support the prognostic significance of HER2/neu in LN-positive breast cancer [22, 23] . On the other hand, HER2/neu prognostic value in patients with LN-negative breast cancer remains controversial. Some studies reported a correlation between HER2/neu amplification and risk of disease recurrence in node-negative breast cancer cases [12, 24] . Others disclosed no correlation between HER2/neu amplification and protein expression in invasive primary breast cancer, with disease outcomes in LN-negative patients [7, 13, 22] . In view of the low risk of relapse and death in LN-negative breast cancer cases, a large sample size and long observation periods are required to detect statistically significant associations between DFS or OS and markers. In this analysis, we employed tissue microarray to examine 359 patients with node-negative breast cancer, with a median follow-up period of 95 months. Our results indicate significant differences between cases with HER2/neu-negative and HER2/neu-positive tumors in terms of 10-year DFS and 10-year OS rates. These findings support previous data showing that HER2/neu is a reliable prognostic marker in the LN-negative group of patients. Furthermore, in multivariate analysis, HER2/neu overexpression was the most important independent variable for DFS and OS, compared with classical prognostic variables such as histologic grade, tumor size, and hormonal status, in LN-negative breast cancer patients.
We additionally observed a highly inverse correlation between HER2/neu expression and hormone receptor status. The subgroup with HER2/neu overexpression and negative hormone receptor status had a particularly poor clinical outcome. Notably, HER2/neu overexpression was a statistically significant marker for poor prognosis, even in subgroups with known poor prognostic factors, such as large tumor size (>2 cm), ER-or PR-negative tumors, or high histologic grades (2 or 3). Based on these observations, we examined the prognostic value of HER2/neu overexpression in combination with the recent St Gallen classification. Remarkably, an 
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approximately twofold elevated risk of relapse and death was observed when tumor specimens showed HER2/neu overexpression in the St Gallen category of 'intermediate' risk of relapse. Our results are consistent with those of a previous study supporting the prognostic utility of a combination of HER2/neu status and the St Gallen classification [15] .
The traditional dogma is that prognostic factors aid physicians to identify breast cancer patients who need adjuvant therapy, whereas predictive factors indicate which adjuvant therapy is most appropriate. As an increasing number of women participate in health screening programs, more LN-negative breast cancer cases are detected today [1] . Therefore, the identification of useful prognostic and reliable predictive factors for the LN-negative group may prevent ineffective treatment and unnecessary side-effects. Although the incremental benefits of adjuvant chemotherapy are controversial [25] , HER2/neu overexpression could be considered as a prognostic factor used to make adjuvant treatment decisions. Our results show that Her2/neu overexpression is an independent poor prognostic factor in LN-negative group, suggesting that this group should be strongly considered for adjuvant chemotherapy.
The therapeutic effects of trastuzumab, a humanized mAb with specificity for the extracellular domain of HER2/neu [26] , used as an adjuvant therapy, are clearly beneficial. In five randomized trials (HERA, combined North American trials, NSABP-B31 and NCCTG/N9831, BCIRG 006, and FinHer trials), trastuzumab markedly reduced recurrence rates by 39%-52% (with high statistical significance) at median followup periods ranging from 1 year to 36 months [27] [28] [29] [30] . Among the trials cited, only the HERA and BCIRG 006 studies included a substantial proportion of patients with LN-negative disease, whereas the other trials included a very low percentage of, or no, LN-negative patients. In particular, subgroup analyses in the HERA trial report revealed that patients with LN-negative disease gained substantially from the use of trastuzumab and indeed even those with small tumors showed treatment benefits. As HER2/neu overexpression in LN-negative breast cancer is related to poor prognosis, active administration of adjuvant trastuzumab should be considered for this group.
Microarray analysis is an innovative technique used to identify gene expression profiles with the aim of identifying better predictive factors for response to chemotherapy. A study by van de Vijver et al. [31] classified 295 patients with stage I or II breast cancer into poor or good prognosis groups, on the basis of gene expression signatures. More recently, the National Surgical Adjuvant Breast and Bowel Cancer Project group further explored the 21-gene signature from node-negative, ER-positive, and tamoxifen-treated patients and developed the 21-gene recurrence score as an independent prognostic factor [32] . However, the use of microarray analysis and gene expression profiling as prognostic and predictive factors for node-negative disease has several limitations in therapy selection, and none of these profiles have been accepted for general use in the clinic. In this respect, hormonal receptor and HER2/neu status, that are easily measurable, may be useful in clinical practice.
In conclusion, our data show that HER2/neu overexpression is an important independent prognostic factor in LN-negative breast cancer patients and support the idea that more intensive adjuvant chemotherapy should be considered in such a population. In addition, measurement of both HER2/neu status and hormone receptor status may facilitate identification of a LN-negative breast cancer subgroup with the worst clinical prognosis. Based on these results, we propose that a combination of HER2/neu status and St Gallen classification is effective to predict the risk of relapse and death in LN-negative breast cancer patients at category of intermediate risk of relapse.
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